Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)

Valentina I. Petkov; Dave P. Miller; Nadia Howlader; Nathan Gliner; Will Howe; Nicola Schussler; Kathleen Cronin; Frederick L. Baehner; Rosemary Cress; Dennis Deapen; Sally L. Glaser; Brenda Y. Hernandez; Charles F. Lynch; Lloyd Mueller; Ann G. Schwartz; Stephen M. Schwartz; Antoinette Stroup; Carol Sweeney; Thomas C. Tucker; Kevin C. Ward; Charles Wiggins; Xiao Cheng Wu; Lynne Penberthy; Steven Shak

doi:10.1038/s41523-018-0069-3

Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)

Valentina I. Petkov, Dave P. Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola Schussler, Kathleen Cronin, Frederick L. Baehner, Rosemary Cress, Dennis Deapen, Sally L. Glaser, Brenda Y. Hernandez, Charles F. Lynch, Lloyd Mueller, Ann G. Schwartz, Stephen M. Schwartz, Antoinette Stroup, Carol Sweeney, Thomas C. Tucker, Kevin C. WardCharles Wiggins, Xiao Cheng Wu, Lynne Penberthy, Steven Shak

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the PDF and HTML versions of this paper.

Original language	English
Article number	17
Journal	npj Breast Cancer
Volume	4
Issue number	1
DOIs	https://doi.org/10.1038/s41523-018-0069-3
State	Published - Dec 1 2018

Bibliographical note

Publisher Copyright:
© 2018, The Author(s).

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41523-018-0069-3

Cite this

Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., ... Shak, S. (2018). Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17). npj Breast Cancer, 4(1), Article 17. https://doi.org/10.1038/s41523-018-0069-3

@article{8c9bd8c7a98343f18733f64ed6365ccb,

title = "Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)",

abstract = "In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the PDF and HTML versions of this paper.",

author = "Petkov, {Valentina I.} and Miller, {Dave P.} and Nadia Howlader and Nathan Gliner and Will Howe and Nicola Schussler and Kathleen Cronin and Baehner, {Frederick L.} and Rosemary Cress and Dennis Deapen and Glaser, {Sally L.} and Hernandez, {Brenda Y.} and Lynch, {Charles F.} and Lloyd Mueller and Schwartz, {Ann G.} and Schwartz, {Stephen M.} and Antoinette Stroup and Carol Sweeney and Tucker, {Thomas C.} and Ward, {Kevin C.} and Charles Wiggins and Wu, {Xiao Cheng} and Lynne Penberthy and Steven Shak",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41523-018-0069-3",

language = "English",

volume = "4",

number = "1",

}

Petkov, VI, Miller, DP, Howlader, N, Gliner, N, Howe, W, Schussler, N, Cronin, K, Baehner, FL, Cress, R, Deapen, D, Glaser, SL, Hernandez, BY, Lynch, CF, Mueller, L, Schwartz, AG, Schwartz, SM, Stroup, A, Sweeney, C, Tucker, TC, Ward, KC, Wiggins, C, Wu, XC, Penberthy, L & Shak, S 2018, 'Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)', npj Breast Cancer, vol. 4, no. 1, 17. https://doi.org/10.1038/s41523-018-0069-3

Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17). / Petkov, Valentina I.; Miller, Dave P.; Howlader, Nadia et al.
In: npj Breast Cancer, Vol. 4, No. 1, 17, 01.12.2018.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to

T2 - Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)

AU - Petkov, Valentina I.

AU - Miller, Dave P.

AU - Howlader, Nadia

AU - Gliner, Nathan

AU - Howe, Will

AU - Schussler, Nicola

AU - Cronin, Kathleen

AU - Baehner, Frederick L.

AU - Cress, Rosemary

AU - Deapen, Dennis

AU - Glaser, Sally L.

AU - Hernandez, Brenda Y.

AU - Lynch, Charles F.

AU - Mueller, Lloyd

AU - Schwartz, Ann G.

AU - Schwartz, Stephen M.

AU - Stroup, Antoinette

AU - Sweeney, Carol

AU - Tucker, Thomas C.

AU - Ward, Kevin C.

AU - Wiggins, Charles

AU - Wu, Xiao Cheng

AU - Penberthy, Lynne

AU - Shak, Steven

PY - 2018/12/1

Y1 - 2018/12/1

N2 - In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the PDF and HTML versions of this paper.

AB - In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the PDF and HTML versions of this paper.

UR - http://www.scopus.com/inward/record.url?scp=85056739472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056739472&partnerID=8YFLogxK

U2 - 10.1038/s41523-018-0069-3

DO - 10.1038/s41523-018-0069-3

M3 - Comment/debate

AN - SCOPUS:85056739472

VL - 4

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 17

ER -

Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this